Skip to content

Laparoscopic and open hepatectomy in the treatment of primary liver cancer: a single-center retrospective study

Laparoscopic and open hepatectomy in the treatment of primary liver cancer: a single-center retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103067
Enrollment
Unknown
Registered
2025-05-23
Start date
2024-07-11
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Laparoscopic hepatectomy group:NA
Open hepatectomy group:NA

Sponsors

Tongji Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 to 80 years. 2. Postoperative pathological diagnosis confirmed primary liver cancer. 3. The enhanced CT scan of the upper abdomen, contrast-enhanced ultrasound, or MRI findings reveal: hepatocellular carcinoma, with no tumor thrombus observed in the portal vein, hepatic veins, inferior vena cara, or bile ducts, and no evidence of extrahepatic metastasis. 4. Individuals with preoperative normal bilirubin levels, liver function categorized as Child-Pugh class A or B, and no severe portal hypertension or active hepatitis. 5. Postoperative follow-up data is complete.

Exclusion criteria

Exclusion criteria: 1. Preoperative bilirubin abnormal >50 umol/L; 2. Liver function Chid-Pugh grade C; 3. Patients with severe portal hypertension before surgery; 4. Patients with active hepatitis preoperatively; 5. Postoperative pathological diagnosis of non-primary liver cancer, intraoperative tumor metastasis or other systemic tumors; 6. Patients with bile duct or vascular cancer thrombus; 7. Patients with other chronic liver diseases such as autoimmune liver disease, or other genetic and metabolic diseases affect the prognosis of the latter; 8. History of long-term use of drugs that impair liver function or have significant side effects; 9. The medical history is unknown, or there is a history of alcoholism, exposure to poisons or special drugs, etc;

Design outcomes

Primary

MeasureTime frame
Overall survival, OS;Disease-free survival, DFS;complete remission, CR;partial remission;

Secondary

MeasureTime frame
Complication rate;Length of hospital stay;Hospitalization costs;

Countries

China

Contacts

Public ContactWeifeng Tan

Tongji Hospital of Tongji University

20537@renji.com+86 18918811855

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026